Kai Rosport,
Head of CMC

Kai joined Ridgeline Discovery in 2021 as VP CMC for protein-based therapies with over 20 years of experience in early and late-stage drug development in small and mid-sized Biotech. Prior to Ridgeline, Kai served as Head of External Supplier Relations and Technical Project Lead at MorphoSys AG in Germany .

At MorphoSys, Kai successfully led the technical development of multiple therapeutic antibody assets up to BLA and commercialization. She has a strong background in large molecule process and analytical technologies, regulatory CMC, clinical supply as well as in project management. Previous roles included Research Scientist at the Technical University of Munich from where she joined a spin-off in the area of cardiovascular drug discovery and development and contributed to the foundation and built of small biotech companies.

Kai holds a degree in Biotechnology from the from the University of Applied Sciences in Emden, Germany.